1024583-33-2

Basic information

• Product Name: methyl 2-bromobenzo[d]thiazole-6-carboxylate
• Synonyms: methyl 2-bromobenzo[d]thiazole-6-carboxylate;2-BroMo-benzothiazole-6-carboxylic acid Methyl ester;2-bromobenzo[d]thiazole-6-carboxylate;Methyl 2-bromobenzo[d]thiazole-6-carboxylat
• CAS NO: 1024583-33-2
• Molecular Formula: C₉H₆BrNO₂S
• Molecular Weight: 272.11844
• Mol File: 1024583-33-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 367.2±34.0 °C(Predicted)
• Appearance: /
• Density: 1.697
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.43±0.10(Predicted)
• CAS DataBase Reference: methyl 2-bromobenzo[d]thiazole-6-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-bromobenzo[d]thiazole-6-carboxylate(1024583-33-2)
• EPA Substance Registry System: methyl 2-bromobenzo[d]thiazole-6-carboxylate(1024583-33-2)

Safety Data

• Hazardous Substances Data: 1024583-33-2(Hazardous Substances Data)

Usage

General Description

Methyl 2-bromobenzo[d]thiazole-6-carboxylate is a chemical compound that belongs to the group of aromatic compounds known as benzo[d]thiazoles. It consists of a benzene ring fused with a thiazole ring, with a methyl group and a carboxylate ester attached to different positions of the benzene ring. The presence of the bromine atom further adds to its molecular structure. methyl 2-bromobenzo[d]thiazole-6-carboxylate has diverse applications in various industries, including pharmaceuticals and agrochemicals, due to its potential as a building block for the synthesis of more complex compounds. However, it is important to note that detailed research and specific usage guidelines should be followed to ensure safe handling and utilization of this chemical.

Upstream product

• 93-85-6 2-aminobenzothiazole-6-carboxylic acid 
• 22514-58-5 2-bromobenzo[d]thiazole-6-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 66947-92-0 2-aminobenzo[d]thiazole-6-carboxylic acid methyl ester 
• 619-45-4 4-methoxycarbonyl aniline 

Downstream Products

• 22514-58-5 2-bromobenzo[d]thiazole-6-carboxylic acid 
• 1224465-39-7 methyl 2-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)benzo[d]thiazole-6-carboxylate 
• 1620069-92-2 C₂₇H₂₁N₃O₅S 
• 1620069-94-4 C₂₇H₂₀N₃O₅S^(1-)*Na⁽¹⁺⁾ 
• 1620074-46-5 C₂₈H₂₃N₃O₅S 
• 1025452-30-5 2-bromobenzo[d]thiazole-6-carbaldehyde 

Relevant articles and documents

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.